First, we transfected both malignant neuroblastoma cell lines with LC3 shRNA plasmid for different time periods (0, 6, 12, and 24 h) and performed Western blotting to assess changes in expression of LC3 I and LC3 II forms (Figure 4a). The gene discussed is MAP1LC3A; the disease is neuroblastoma.